Yes, agreed regarding the selling is done. This should trade back up to the CR price before end Nov'24.
I'm also expecting some Ovarian preclinical test results by then, which will further highlight Narma's potential.
Biotech ETF also indicates money rotation (albeit slow for now) to this sector.
Accumulating.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
-0.005(2.08%) |
Mkt cap ! $91.57M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $766.6K | 3.262M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 179879 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 402089 | 6 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |